Case of the combined application of cognitive-behavior therapy and zopiclone in chronic insomnia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Insomnia is characterized by the difficulties in falling asleep and sleep maintenance, and various types of disorders of day-to-day functioning. «Insomnia» both as a symptom and as disease has serious professional and social consequences, affecting daytime activity and professional abilities. The main role in the pathogenesis of insomnia is played by the state of cerebral hyperactivation, which has cognitive, electrophysiological and metabolic manifestations. The method of choice in the treatment of most forms of insomnia is cognitive-behavioral therapy. Third generation hypnotics are the most common pharmacological treatments for insomnia, and zopiclone occupies one of the leading places among them.

Full Text

Restricted Access

About the authors

S. L Tsenteradze

FSAEI HE “I.M. Sechenov First Moscow State Medical University" of MHRF

Email: s.tsenteradze@mail.iu
NeurologisT., Department of Sleep Medicine UCH № 3

M. G Poluektov

FSAEI HE “I.M. Sechenov First Moscow State Medical University" of MHRF

P. V Pchelina

FSAEI HE “I.M. Sechenov First Moscow State Medical University" of MHRF

References

  1. American Academy of Sleep medicine: international classification of sleep disorders, 3rd ed.: diagnostic and coding manual. Darien, IL: American Academy of Sleep Medicine, 2014.
  2. Сомнология и медицина сна. Национальное руководство памяти А.М. Вейна и Я.И. Левина /Под ред. М.Г Полуэктова. М., 2016.
  3. Livingston G., Blizard B, Mann A. Does sleep disturbance predict depression in elderly people? A study in inner London. Br. J. Gen. Pract. 1993;43(376):445-48.
  4. Leger D., Scheuermaier K., Philip P., et al. SF-36: Evaluation of quality of life in severe and mild insomniacs compared with good sleepers. Psychosom. Med. 2001;63:49-55.
  5. Schutte-Rodin S., Broch L., Buysse D., Dorsey C., Sateia M. Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults. J. Clin. Sleep Med. 2008;4(5):487-504.
  6. Berry R.B., Budhiraja R., Gottlieb D.J., Gozal D., Iber C., Kapur V.K., Marcus C.L., Mehra R., Parthasarathy S., Quan S.F, Redline S., Strohl K.P., Davidson Ward S.L., Tangredi M.M. Rules for scoring respiratory events in sleep: Update of the 2007 AASM manual for the scoring of sleep and associated events. J Clin Sleep Med 2012;8:597-619.
  7. Morin С., Belleville G., Belanger L. The ISI: Psychometric Indicators to detect Insomnia Cases and Evaluate Treatment Response. Sleep. 2011; 34(5): 601-8.
  8. Buysse D.J., Reynolds C.F.,Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index (PSQI): a new instrument for psychiatric research and practice. Psychiatry Res. 1989;28: 193-213.
  9. Beck, A.T., Steer, R.A., & Garbin, M.G. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin. Psychol. Rev. 1988;8(1):77-100.
  10. Исследование тревожности (Ч.Д. Спилбергер, адаптация Ю.Л. Ханин). Диагностика эмоционально-нравственного развития. Ред. и сост. И.Б. Дерманова. СПб., 2002. С. 124-26.
  11. Mastin, D.F., Bryson, J., Corwyn, R. Assessment of sleep hygiene using the Sleep Hygiene Index. J. Behavioral Med. 2006;29(3):223-27.
  12. Тхостов А.Ш., Рассказова Е.И. Шкала дисфункциональных убеждений в отношении сна. Учебно-методическое пособие. М., 2007.
  13. Mason E.C., Harvey A.G. Insomnia before and after treatment for anxiety and depression. J. Affective Dis. 2014;168:415-21.
  14. Drover D.R. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin. Pharmacokinet. 2004;43(4):227-38.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies